Prevail Therapeutics will soon start its Phase 1/2 clinical trial evaluating the safety, tolerability, and early efficacy of…
Articles by Patricia Inácio, PhD
The U.S Food and Drug Administration (FDA) has approved Kyowa Kirin’s Nourianz (istradefylline) tablets as an add-on therapy…
Rescuing the activity of neurons in the subthalamic nucleus — part of a brain region that controls movement — lessens…
The largest dataset ever compiled on Parkinson’s disease research — equivalent to 47.5 billion single-spaced typed pages — is now…
A scientist at the University of Sheffield in England has been awarded a £100,000 grant by Parkinson’s UK to…
Scientist Wenquan Zou, MD, PhD, has received a two-year grant to develop a non-invasive skin test for diagnosing…
The Multiple Sclerosis (MS) and Parkinson’s Tissue Bank at Imperial College London, is the largest repository of brain…
The Committee for Medicinal Products for Human Use (CHMP) — an arm of the European Medicines Agency (EMA) —…
Therapies against motor loss and progression in Parkinson’s’ disease (PD) may need to tackle the imbalance between two neurotransmitters,…
The U.S. Food and Drug Administration has accepted Neurocrine Biosciences’ new drug application for opicapone as a potential add-on…